The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy.
Anti-tumour necrosis factor antagonists have appreciably improved patient outcomes in Crohn's disease, shifting the goals of treatment from control of symptoms to clinical remission (Crohn's disease activity index <150) combined with mucosal healing - the new concept of 'deep r...
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
2012
|